(Sharecast News) - Shares in Danish biotech group Genmab jumped to a three-year high on Tuesday after a late-stage trial of its lymphoma treatment developed with AbbVie delivered better outcomes than the current standard therapy.
Genmab and AbbVie said their drug epcoritamab, when added to the existing standard treatment for...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE